Nutriband Inc. has successfully patented its abuse-deterrent transdermal technology in 46 countries, including key markets like the U.S., Europe, and China. The company is planning to file for FDA ...

Nutriband Inc., a company primarily focused on the development of prescription transdermal pharmaceutical products, recently disclosed its completion of registration requirements to extend its Chinese ...

ORLANDO, Fla., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders highlighting the ...

Over the past month in Ontario, officers with three different police agencies were taken to hospital following exposure to ...

Anodyne Nanotech, a clinical-stage biotech company, today announced promising preclinical results for its proprietary HeroPatch™ platform, demonstrating the ability to transdermally deliver ...

If approved, AVERSA Fentanyl could become the first and only abuse-deterrent transdermal patch available globally. AVERSA Fentanyl is estimated to have the potential to reach peak annual sales of ...

Nutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets.Nutriband is ...

AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl ...